PF30

PF30 is a preclinical biopharmaceutical candidate being developed by Medytox for the treatment of glabellar lines (frown lines). As an early-stage asset in Medytox's aesthetic pipeline, it is categorized as a biopharmaceutical, though specific details regarding its molecular structure and exact mechanism of action have not been publicly disclosed. Medytox is a South Korean company primarily known for its portfolio of botulinum toxin products, suggesting that PF30 may be a novel neuromodulator or biological treatment intended for aesthetic applications. The drug is currently undergoing discovery and preclinical evaluation.